Marker Therapeutics, Inc. Common Stock (MRKR) Stock Price

MRKRStock

$1.52+16.28%52W

Market Cap$25.34M

P/E—

PEG Ratio—

Div yield—

Beta1.48

MRKR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-11.25%

Price vs S&P 500 (4W)24.07%

VGM Score57.68

Book Value / Share (Quarterly)$0.83

P/TBV (Annual)1.27x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-26.71%

Cash Flow / Share (Quarterly)$-0.47

Price vs S&P 500 (YTD)-11.29%

Net Profit Margin (TTM)-342.96%

EPS (TTM)$-0.90

10-Day Avg Trading Volume0.09M

EPS Excl Extra (TTM)$-0.90

Revenue Growth (5Y)49.81%

EPS (Annual)$-0.79

ROI (Annual)-72.42%

Net Profit Margin (5Y Avg)-892.83%

Cash / Share (Quarterly)$0.89

Revenue Growth QoQ (YoY)-51.00%

ROA (Last FY)-63.78%

Revenue Growth TTM (YoY)-46.19%

EBITD / Share (TTM)$-0.84

ROE (5Y Avg)-87.35%

Operating Margin (TTM)-363.45%

Cash Flow / Share (Annual)$-0.72

P/B Ratio1.35x

P/B Ratio (Quarterly)1.57x

Net Income / Employee (Annual)$-2,432,700

EV / Revenue (TTM)1.06x

Net Interest Coverage (TTM)-0.22x

ROA (TTM)-67.05%

EPS Incl Extra (Annual)$-0.79

Current Ratio (Annual)8.39x

Quick Ratio (Quarterly)4.68x

3-Month Avg Trading Volume0.07M

52-Week Price Return16.28%

Revenue / Employee (TTM)$709,300

Tangible BV / Share (Quarterly)$1.90

P/S Ratio (Annual)5.27x

Asset Turnover (Annual)0.19x

52-Week High$2.46

Operating Margin (5Y Avg)-936.98%

EPS Excl Extra (Annual)$-0.79

Tangible BV CAGR (5Y)39.90%

26-Week Price Return0.00%

Quick Ratio (Annual)8.10x

13-Week Price Return4.90%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.79x

Enterprise Value$3.76M

Revenue / Share Growth (5Y)18.30%

Asset Turnover (TTM)0.20x

Book Value / Share Growth (5Y)-28.53%

Revenue / Employee (Annual)$709,300

Pretax Margin (Annual)-343.39%

Cash / Share (Annual)$0.96

3-Month Return Std Dev71.11%

Net Income / Employee (TTM)$-2,432,700

ROE (Last FY)-72.42%

Net Interest Coverage (Annual)-33.36x

EPS Basic Excl Extra (Annual)$-0.79

Receivables Turnover (TTM)6.31x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.90

Receivables Turnover (Annual)7.50x

ROI (TTM)-80.86%

P/S Ratio (TTM)5.27x

Pretax Margin (5Y Avg)-927.83%

Revenue / Share (Annual)$0.23

Tangible BV / Share (Annual)$2.33

Price vs S&P 500 (52W)-2.03%

Year-to-Date Return0.67%

5-Day Price Return30.43%

EPS Normalized (Annual)$-0.79

ROA (5Y Avg)-61.80%

Net Profit Margin (Annual)-342.96%

Month-to-Date Return32.74%

Cash Flow / Share (TTM)$-0.74

EBITD / Share (Annual)$-0.84

Operating Margin (Annual)-363.45%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-87.35%

EPS Basic Excl Extra (TTM)$-0.90

P/TBV (Quarterly)1.48x

P/B Ratio (Annual)1.48x

Pretax Margin (TTM)-343.39%

Book Value / Share (Annual)$1.01

Price vs S&P 500 (13W)2.10%

Beta1.48x

Revenue / Share (TTM)$0.18

ROE (TTM)-80.86%

52-Week Low$0.81

vGradeB

gGradeD

mGradeB

vgmGradeC

MRKR Earnings Surprise History

Q2 25-0.29est. -0.27

Q3 25-0.12est. -0.21

Q4 25-0.04est. -0.19

Q1 26-0.16est. -0.19

Q2 26-0.09est. -0.18

MRKR Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.11

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
MRKRMarker Therapeutics, Inc. Common Stock	B	D	B	$1.52
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Marker Therapeutics, Inc. Common Stock

Marker Therapeutics is a clinical-stage immuno-oncology company developing T cell-based immunotherapies and vaccine candidates for hematological and solid tumors. Its MultiTAA T cell technology selectively expands patient-derived, tumor-specific T cells to target and eliminate cancer cells expressing tumor-associated antigens.